Bortezomib and Rituximab in Treating Patients With Relapsed or Refractory B-Cell Non-Hodgkin's Lymphoma

DISEASE CHARACTERISTICS: * Histologically confirmed B-cell non-Hodgkin's lymphoma (NHL) including the following subtypes: * B-cell small lymphocytic lymphoma * Marginal zone lymphoma (extranodal, nodal, or splenic) * Grade 1-3 follicular lymphoma * Mantle cell lymphoma * Waldenstrom's macroglobulinemia * Bidimensionally measurable disease by CT scan with ≥ 1 lesion measuring \> 1.5 cm in a single dimension * Relapsed or refractory disease after prior antineoplastic therapy, meeting 1 of the following criteria: * No response to prior treatment * Relapsed disease after prior therapy * Confirmed CD20-positive disease by immunohistochemistry on biopsy specimen * Prior transformation allowed provided there is no evidence of aggressive histology on recent biopsy * No chronic lymphocytic lymphoma with absolute lymphocyte count \> 5,000/mm³ * No CNS involvement PATIENT CHARACTERISTICS: * ECOG performance status 0-2 * Absolute neutrophil count ≥ 1,500/mm\^3 (≥ 1,000/mm³ if due to extensive bone marrow involvement with NHL or splenomegaly) * Absolute lymphocyte count ≤ 5,000/mm³ (except mantle cell lymphoma with a leukemic phase) * Platelet count ≥ 50,000/mm\^3 * Bilirubin ≤ 2.0 mg/dL * AST and ALT ≤ 2.5 times upper limit of normal (ULN) (4 times ULN if liver involvement with NHL) * Creatinine ≤ 2.0 mg/dL * Not pregnant or nursing * Negative pregnancy test * Fertile male and female patients must use effective contraception during study * No serious nonmalignant disease * No active infection * No peripheral neuropathy ≥ grade 2 within past 14 days * No myocardial infarction within the past 6 months * No New York Heart Association class III or IV heart failure * No uncontrolled angina pectoris * No severe uncontrolled ventricular arrhythmias * No EKG evidence of acute ischemia or active conduction system abnormalities * Any EKG abnormality must be documented as not medically relevant * No hypersensitivity to bortezomib, boron, or mannitol * No known anaphylaxis or immunoglobulin E-mediated hypersensitivity to murine proteins or any component of rituximab (including polysorbate 80 and sodium citrate dehydrate) * No known infection or exposure to HIV * No serious psychiatric or medical illness that would preclude study participation * No active hepatitis B infection * No other primary malignancy requiring active treatment * More than 4 weeks since prior significant traumatic injury PRIOR CONCURRENT THERAPY: * At least 3 weeks since prior and no concurrent radiotherapy * More than 4 weeks since prior major surgery or open biopsy * Other diagnostic surgery allowed * More than 4 weeks since prior cytotoxic chemotherapy (6 weeks for nitrosoureas) * At least 3 months since prior unconjugated monoclonal antibody therapy * At least 10 weeks since prior radioimmunoconjugates or toxin immunoconjugates (e.g., iodine I 131 tositumomab \[Bexxar\] or ibritumomab tiuxetan \[Zevalin\]) * More than 2 weeks since prior investigational agent * No prior bortezomib * No concurrent systemic corticosteroid at greater than the equivalent dose of 20 mg/day of prednisone, unless for treatment of allergic reactions to CT scan dye * No concurrent major surgery * No other immunosuppressive agents, unless for treatment of allergic reactions to CT scan dye * No other concurrent antilymphoma agents * No other concurrent investigational agent * Concurrent participation in another nontreatment study allowed if it does not interfere with participation in this study